Abstract
Transthyretin is a homotetrameric protein that carries thyroxine and retinol binding protein in plasma and is associated with a variety of amyloid diseases. One approach to the potential treatment of TTR amyloidosis is the stabilization of the native tetramer, over the dissociative transition state, through the binding of small molecules; this increases the kinetic barrier for tetramer dissociation and prevents protein misfolding. Several molecules discovered through focused screening, or created utilizing the structure-based design, were studied to identify the structural features that could make up for a good candidate drug. In this review, we examine several different chemical classes of TTR fibril formation inhibitors, highlighting the structural modifications that have led to an improvement or to a decrease of their potency and/or selectivity.
Keywords: Transthyretin (TTR), TTR-amyloidosis, familial transthyretin amyloidosis (FAP, FAC, SSA), protein-misfolding disorders, TTR amyloid fibril formation inhibitors, structure based drug discovery, amyloid fibril formation inhibitors, SAR
Current Medicinal Chemistry
Title:TTR Fibril Formation Inhibitors: Is there a SAR?
Volume: 19 Issue: 15
Author(s): S. Nencetti, E. Orlandini
Affiliation:
Keywords: Transthyretin (TTR), TTR-amyloidosis, familial transthyretin amyloidosis (FAP, FAC, SSA), protein-misfolding disorders, TTR amyloid fibril formation inhibitors, structure based drug discovery, amyloid fibril formation inhibitors, SAR
Abstract: Transthyretin is a homotetrameric protein that carries thyroxine and retinol binding protein in plasma and is associated with a variety of amyloid diseases. One approach to the potential treatment of TTR amyloidosis is the stabilization of the native tetramer, over the dissociative transition state, through the binding of small molecules; this increases the kinetic barrier for tetramer dissociation and prevents protein misfolding. Several molecules discovered through focused screening, or created utilizing the structure-based design, were studied to identify the structural features that could make up for a good candidate drug. In this review, we examine several different chemical classes of TTR fibril formation inhibitors, highlighting the structural modifications that have led to an improvement or to a decrease of their potency and/or selectivity.
Export Options
About this article
Cite this article as:
S. Nencetti, E. Orlandini , TTR Fibril Formation Inhibitors: Is there a SAR?, Current Medicinal Chemistry 2012; 19 (15) . https://dx.doi.org/10.2174/092986712800269326
DOI https://dx.doi.org/10.2174/092986712800269326 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Ablation of Complex Fractionated Atrial Electrograms in Catheter Ablation for AF; Where have we been and where are we going?
Current Cardiology Reviews Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition An In-Silico Investigation of Anti-Chagas Phytochemicals
Current Clinical Pharmacology Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: The Life Cycle of the Heart Failure Patient)
Current Cardiology Reviews Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Pleiotropic Effect of Statins as Antioxidants on Cardiac Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA MicroRNAs and the Heart: Small Things Do Matter
Current Topics in Medicinal Chemistry Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) Endocrine Orchestration of Cardiovascular, Gastrointestinal and Hypothalamic Control
Current Medicinal Chemistry Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design